PURE Bioscience
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of PURE Bioscience generated cash of -$2,531,000, which is more than the previous year. Cash used in financing activities reached the amount of $1,785,000 last year. Net change in cash is therefore -$746,000.
Cash Flow
| 2015 | -6.06M | -107K | 7.40M |
|---|---|---|---|
| 2016 | -4.99M | -405K | 9.26M |
| 2017 | -4.56M | -226K | 1.23M |
| 2018 | -3.88M | -34K | 3.13M |
| 2019 | -2.99M | -13K | 2.55M |
| 2020 | 669K | -58K | 2.83M |
| 2021 | -1.16M | -521K | 239K |
| 2022 | -2.41M | -81K | 3.5M |
| 2023 | -3.27M | -33K | 1.01M |
| 2024 | -2.53M | 0 | 1.78M |
PURE Cash Flow Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 1.17M | 3.46M | 2.46M | 3.91M | 473K | 926K | 1.64M | 5.19M | 1.32M | 86K |
Operating activities | ||||||||||
Net income | -3.35M | -3.96M | -3.49M | -2.31M | 4K | -6.55M | -7.44M | -6.26M | -14.37M | -7.62M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 148K | 117K | 213K | 172K | 192K | 241K | 285K | 276K | 219K | 206K |
Stock-based compensation expense | 214K | 324K | 567K | 841K | 787K | 2.44M | 0 | 1.07M | 1.90M | 2.38M |
| Deferred income tax benefit | 214K | 324K | 567K | 841K | 787K | 2.44M | 0 | 1.07M | 1.90M | 2.38M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -13K | -84K | 167K | 721K | -716K | -98K | 22K | -34K | -74K | -142K |
Inventories | 32K | 57K | 78K | 65K | -370K | 20K | 37K | 27K | -143K | 42K |
Accounts payable | 201K | -43K | -156K | -781K | 772K | -38K | 148K | -117K | -139K | -955K |
Cash generated by operating activities | -2.53M | -3.27M | -2.41M | -1.16M | 669K | -2.99M | -3.88M | -4.56M | -4.99M | -6.06M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | -33K | -81K | -521K | -58K | -13K | -34K | -226K | -405K | -107K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | -33K | -81K | -521K | -58K | -13K | -34K | -226K | -405K | -107K |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 3.5M | 0 | 2.83M | 1.71M | 51K | 1.04M | 0 | 7.40M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 1.78M | 1.01M | 0 | -239K | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 1.78M | 1.01M | 3.5M | 239K | 2.83M | 2.55M | 3.13M | 1.23M | 9.26M | 7.40M |
Net Change In Cash | -746K | -2.29M | 1.00M | -1.44M | 3.44M | -453K | -789K | -3.55M | 3.87M | 1.23M |
Cash at end of period | 424K | 1.17M | 3.46M | 2.46M | 3.91M | 473K | 851K | 1.64M | 5.19M | 1.32M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |